Artelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial Officer
Artelo Biosciences (Nasdaq: ARTL) named Mark Spring, CPA, as Chief Financial Officer, effective November 1, 2025.
Mr. Spring has served as a financial consultant to Artelo since December 2024 and brings 30 years of life‑sciences financial leadership, including interim CFO and CFO roles at multiple commercial and development‑stage companies and significant M&A and licensing experience. The appointment is presented as strengthening financial leadership as Artelo advances its clinical pipeline and corporate growth initiatives.
Artelo Biosciences (Nasdaq: ARTL) ha nominato Mark Spring, CPA, come Chief Financial Officer, con effetto dal 1 novembre 2025.
Il signor Spring ha lavorato come consulente finanziario per Artelo dal dicembre 2024 e porta con sé 30 anni di leadership finanziaria nel settore delle scienze della vita, includendo ruoli di CFO ad interim e CFO presso numerose aziende sia commerciali sia in fase di sviluppo, oltre a significative esperienze in fusioni e acquisizioni e licensing. La nomina è presentata come un rafforzamento della leadership finanziaria mentre Artelo prosegue con il suo pipeline clinico e le iniziative di crescita aziendale.
Artelo Biosciences (Nasdaq: ARTL) designó a Mark Spring, CPA, como Director Financiero, con efecto a partir del 1 de noviembre de 2025.
El señor Spring ha servido como asesor financiero para Artelo desde diciembre de 2024 y aporta 30 años de liderazgo financiero en las ciencias de la vida, incluyendo roles de CFO interino y CFO en múltiples empresas comerciales y en fase de desarrollo, así como una experiencia significativa en fusiones y adquisiciones y licencias. El nombramiento se presenta como un fortalecimiento del liderazgo financiero a medida que Artelo avanza en su portafolio clínico y las iniciativas de crecimiento corporativo.
Artelo Biosciences (Nasdaq: ARTL)는 Mark Spring, CPA를 최고재무책임자(CFO)로 지명했으며, 효력은 2025년 11월 1일부터입니다.
Spring 씨는 2024년 12월부터 Artelo의 재무 자문으로 활동해 왔으며, 생명과학 분야에서 30년의 재무 리더십을 보유하고 있습니다. 임시 CFO 및 다수의 상용 및 개발 단계 기업에서의 CFO 역할과 M&A 및 라이선스 관련 풍부한 경험을 포함합니다. 이번 임명은 Artelo가 임상 파이프라인과 기업 성장 이니셔티브를 추진함에 따라 재무 리더십을 강화하기 위한 것입니다.
Artelo Biosciences (Nasdaq: ARTL) a nommé Mark Spring, CPA, au poste de directeur financier, avec effet au 1er novembre 2025.
M. Spring a travaillé comme consultant financier pour Artelo depuis décembre 2024 et apporte 30 ans de leadership financier dans le secteur des sciences de la vie, y compris des postes de CFO intérimaire et CFO dans plusieurs entreprises commerciales et en phase de développement, ainsi qu'une expérience significative en fusions et acquisitions et en licences. Cette nomination est présentée comme un renforcement du leadership financier à mesure qu'Artelo fait progresser son pipeline clinique et ses initiatives de croissance de l'entreprise.
Artelo Biosciences (Nasdaq: ARTL) ernennt Mark Spring, CPA, zum Chief Financial Officer, mit Wirkung zum 1. November 2025.
Herr Spring hat seit Dezember 2024 als Finanzberater für Artelo gearbeitet und verfügt über 30 Jahre Führungserfahrung im Finanzwesen der Lebenswissenschaften, einschließlich Interim-CFO- und CFO-Positionen bei mehreren kommerziellen und entwicklungsstufen Unternehmen sowie erhebliche Erfahrungen in M&A und Lizenzierung. Die Berufung wird als Stärkung der Finanzführung gesehen, während Artelo seine klinische Pipeline und Unternehmenswachstumsinitiativen vorantreibt.
Artelo Biosciences (Nasdaq: ARTL) أعلنت تعيين مارك سبرينغ، CPA، في منصب المدير المالي، اعتباراً من 1 نوفمبر 2025.
لقد عمل السيد سبرينغ كمستشار مالي لـ Artelo منذ ديسمبر 2024 ويجلب معه 30 عامًا من القيادة المالية في علوم الحياة، بما في ذلك أدوار CFO بالإنابة وCFO في عدة شركات تجارية وفي مراحل التطوير وخبرة كبيرة في الاندماج والاستحواذ والتراخيص. وتُقدَّم التعيين كتعزيز للقيادة المالية مع تقدم Artelo في خطها السريري ومبادرات النمو المؤسسي.
Artelo Biosciences (Nasdaq: ARTL) 任命 Mark Spring, CPA，担任首席财务官，生效日期为 2025年11月1日。
Spring 先生自 2024年12月起一直为 Artelo 提供财务顾问服务，带来 30年生命科学领域的财务领导经验，包括多家商业化及开发阶段公司的过渡性CFO 与 CFO 角色，以及在并购与许可方面的丰富经验。此次任命被视为在 Artelo 推进其临床管线与公司增长计划之际加强财务领导。
- CFO appointment effective November 1, 2025
- 30 years of life‑sciences financial leadership experience
- Consultant to Artelo since December 2024, providing continuity
- None.
SOLANA BEACH, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today announced the appointment of Mark Spring, CPA, as Chief Financial Officer, effective November 1, 2025. Mr. Spring had been serving as a financial consultant to the Company since December 2024. The appointment strengthens Artelo’s financial leadership as it advances its clinical pipeline and corporate growth initiatives.
Mark Spring brings 30 years of experience in life sciences to his role, including financial leadership of private and public, domestic and multinational, commercial and development stage companies. Mr. Spring recently served as interim CFO for LENZ Therapeutics through its reverse merger transaction and was co-founder and CFO of Secura Bio, a commercial-stage oncology therapeutics company. He also served as CFO for Hyperion Therapeutics, Prometheus Laboratories, Veracyte, Sotera Wireless, and Genoptix. Mr. Spring has extensive M&A and licensing experience with significant roles in major transactions at Caremark, Dade Behring, Baxter, MedImmune, Prometheus and Genoptix. He holds a BA in Business Administration from Monmouth College, completed postgraduate studies at the University of Texas at Dallas, and is a Certified Public Accountant (active).
“Mark’s extensive experience across commercial-stage and development-stage biopharmaceutical companies makes him an outstanding addition to our leadership team,” said Gregory Gorgas, President and Chief Executive Officer of Artelo Biosciences. “Since his engagement in December, Mark has strengthened our financial operations, supported the execution of our capital strategy, and enhanced our shareholder communications. His experience and steady leadership are expected to be instrumental as we advance our product candidates and build shareholder value.”
“I have developed strong conviction in Artelo’s strategy, development programs and leadership,” said Mark Spring. “Working closely with the team has given me a clear view of the Company’s operational strengths, prudent approach to capital allocation, and commitment to advancing high-value programs. I’m confident in Artelo’s potential and look forward to helping drive disciplined financial execution and long-term growth.”
About Artelo Biosciences, Inc.
Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the Company applies leading-edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and X: @ArteloBio.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws.
Investor Relations Contact:
Crescendo Communications, LLC
Tel: 212-671-1020
Email: ARTL@crescendo-ir.com
FAQ
When does Artelo (ARTL) expect Mark Spring to start as CFO?
What prior role did Mark Spring hold with Artelo before becoming CFO of ARTL?
What experience does the new Artelo (ARTL) CFO Mark Spring have in life sciences?
How might Artelo investors view the ARTL CFO appointment on Nov 1, 2025?
Is Mark Spring a licensed accountant for his ARTL CFO role?
Does the Artelo press release state Mark Spring's role in transactions relevant to ARTL strategy?
